Spectral Medical Inc. (Spectral), formerly Spectral Diagnostics Inc., is a therapeutic development company. Spectral is focused on the development and commercialization of a treatment for severe sepsis and septic shock utilizing its Endotoxin Activity Assay (EAA) and the Toraymyxin (PMX) therapeutic. The Company also manufactures and sells certain reagents. The Company's only clinical development program is for PMX. Spectral is engaged in the development of biochemical markers for the clinical syndrome known as septic shock. The Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. Spectral develops, produces and markets recombinant proteins, antibodies and calibrators.